Unsupervised Protein-Ligand Binding Energy Prediction via Neural Euler's Rotation Equation

Protein-ligand binding prediction is a fundamental problem in AI-driven drug discovery. Prior work focused on supervised learning methods using a large set of binding affinity data for small molecules, but it is hard to apply the same strategy to other drug classes like antibodies as labelled data is limited. In this paper, we explore unsupervised approaches and reformulate binding energy prediction as a generative modeling task. Specifically, we train an energy-based model on a set of unlabelled protein-ligand complexes using SE(3) denoising score matching and interpret its log-likelihood as binding affinity. Our key contribution is a new equivariant rotation prediction network called Neural Euler's Rotation Equations (NERE) for SE(3) score matching. It predicts a rotation by modeling the force and torque between protein and ligand atoms, where the force is defined as the gradient of an energy function with respect to atom coordinates. We evaluate NERE on protein-ligand and antibody-antigen binding affinity prediction benchmarks. Our model outperforms all unsupervised baselines (physics-based and statistical potentials) and matches supervised learning methods in the antibody case.

Antibody-Antigen Docking and Design via Hierarchical Equivariant Refinement

Computational antibody design seeks to automatically create an antibody that binds to an antigen. The binding affinity is governed by the 3D binding interface where antibody residues (paratope) closely interact with antigen residues (epitope). Thus, predicting 3D paratope-epitope complex (docking) is the key to finding the best paratope. In this paper, we propose a new model called Hierarchical Equivariant Refinement Network (HERN) for paratope docking and design. During docking, HERN employs a hierarchical message passing network to predict atomic forces and use them to refine a binding complex in an iterative, equivariant manner. During generation, its autoregressive decoder progressively docks generated paratopes and builds a geometric representation of the binding interface to guide the next residue choice. Our results show that HERN significantly outperforms prior state-of-the-art on paratope docking and design benchmarks.

Iterative Refinement Graph Neural Network for Antibody Sequence-Structure Co-design

Antibodies are versatile proteins that bind to pathogens like viruses and stimulate the adaptive immune system. The specificity of antibody binding is determined by complementarity-determining regions (CDRs) at the tips of these Y-shaped proteins. In this paper, we propose a generative model to automatically design the CDRs of antibodies with enhanced binding specificity or neutralization capabilities. Previous generative approaches formulate protein design as a structure-conditioned sequence generation task, assuming the desired 3D structure is given a priori. In contrast, we propose to co-design the sequence and 3D structure of CDRs as graphs. Our model unravels a sequence autoregressively while iteratively refining its predicted global structure. The inferred structure in turn guides subsequent residue choices. For efficiency, we model the conditional dependence between residues inside and outside of a CDR in a coarse-grained manner. Our method achieves superior log-likelihood on the test set and outperforms previous baselines in designing antibodies capable of neutralizing the SARS-CoV-2 virus.

Modeling Drug Combinations based on Molecular Structures and Biological Targets

Drug combinations play an important role in therapeutics due to its better efficacy and reduced toxicity. Since validating drug combinations via direct screening is prohibitively expensive due to combinatorial explosion, recent approaches have applied machine learning to identify synergistic combinations for cancer. However, these approaches is not readily applicable to many diseases with limited combination data. Motivated by the fact that drug synergy is closely tied with biological targets, we propose a model that jointly learns drug-target interaction and drug synergy. The model, parametrized as a graph convolutional network, consists of two parts: a drug-target interaction and target-disease association module. These modules are trained together on drug combination screen as well as abundant drug-target interaction data. Our model is trained and evaluated on two SARS-CoV-2 drug combination screens and achieves 0.777 test AUC, which is 10% higher than the model trained without drug-target interaction.

Domain Extrapolation via Regret Minimization

Many real prediction tasks such as molecular property prediction require ability to extrapolate to unseen domains. The success in these tasks typically hinges on finding a good representation. In this paper, we extend invariant risk minimization (IRM) by recasting the simultaneous optimality condition in terms of regret, finding instead a representation that enables the predictor to be optimal against an oracle with hindsight access on held-out environments. The change refocuses the principle on generalization and doesn't collapse even with strong predictors that can perfectly fit all the training data. Our regret minimization (RGM) approach can be further combined with adaptive domain perturbations to handle combinatorially defined environments. We evaluate our method on two real-world applications: molecule property prediction and protein homology detection and show that RGM significantly outperforms previous state-of-the-art domain generalization techniques.

Improved Conditional Flow Models for Molecule to Image Synthesis

In this paper, we aim to synthesize cell microscopy images under different molecular interventions, motivated by practical applications to drug development. Building on the recent success of graph neural networks for learning molecular embeddings and flow-based models for image generation, we propose Mol2Image: a flow-based generative model for molecule to cell image synthesis. To generate cell features at different resolutions and scale to high-resolution images, we develop a novel multi-scale flow architecture based on a Haar wavelet image pyramid. To maximize the mutual information between the generated images and the molecular interventions, we devise a training strategy based on contrastive learning. To evaluate our model, we propose a new set of metrics for biological image generation that are robust, interpretable, and relevant to practitioners. We show quantitatively that our method learns a meaningful embedding of the molecular intervention, which is translated into an image representation reflecting the biological effects of the intervention.

Adaptive Invariance for Molecule Property Prediction

Effective property prediction methods can help accelerate the search for COVID-19 antivirals either through accurate in-silico screens or by effectively guiding on-going at-scale experimental efforts. However, existing prediction tools have limited ability to accommodate scarce or fragmented training data currently available. In this paper, we introduce a novel approach to learn predictors that can generalize or extrapolate beyond the heterogeneous data. Our method builds on and extends recently proposed invariant risk minimization, adaptively forcing the predictor to avoid nuisance variation. We achieve this by continually exercising and manipulating latent representations of molecules to highlight undesirable variation to the predictor. To test the method we use a combination of three data sources: SARS-CoV-2 antiviral screening data, molecular fragments that bind to SARS-CoV-2 main protease and large screening data for SARS-CoV-1. Our predictor outperforms state-of-the-art transfer learning methods by significant margin. We also report the top 20 predictions of our model on Broad drug repurposing hub.

Improving Molecular Design by Stochastic Iterative Target Augmentation

Generative models in molecular design tend to be richly parameterized, data-hungry neural models, as they must create complex structured objects as outputs. Estimating such models from data may be challenging due to the lack of sufficient training data. In this paper, we propose a surprisingly effective self-training approach for iteratively creating additional molecular targets. We first pre-train the generative model together with a simple property predictor. The property predictor is then used as a likelihood model for filtering candidate structures from the generative model. Additional targets are iteratively produced and used in the course of stochastic EM iterations to maximize the log-likelihood that the candidate structures are accepted. A simple rejection (re-weighting) sampler suffices to draw posterior samples since the generative model is already reasonable after pre-training. We demonstrate significant gains over strong baselines for both unconditional and conditional molecular design. In particular, our approach outperforms the previous state-of-the-art in conditional molecular design by over 10% in absolute gain.